🇺🇸 FDA
Patent

US 11427816

Cancer treatment through RLIP76 partial depletion

granted A61PA61P35/00

Quick answer

US patent 11427816 (Cancer treatment through RLIP76 partial depletion) held by The Board of Regents of the University of Texas System expires Mon Aug 25 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Board of Regents of the University of Texas System
Grant date
Tue Aug 30 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 25 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
13
CPC classes
A61P, A61P35/00